We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Preventing people in England from developing high blood pressure (hypertension), and detecting and managing it better in those who have it.
Guidance and additional resources about the 'opt-out' testing policy for blood-borne viruses in prisons and other secure settings.
How to use an interrupted time series to evaluate your digital health product.
Information and service documents on the national DBS testing service offered by PHE to improve uptake of 12 month testing of infants born to hepatitis B infected mothers.
Estimates of the cardiovascular disease events and costs avoided from increasing blood pressure checks in community pharmacies in England.
Evidence-based advice for partners including local government and the health system on how to effectively identify, treat and prevent high blood pressure (hypertension).
The NHSBT and UKHSA surveillance programme is a series of national schemes that monitors infection in blood, tissue and organ donors, and transfusion recipients.
The NHSBT / PHE epidemiology unit, and the epidemiology of infections among blood, tissue and organ donors and recipients.
You must tell DVLA if you have high blood pressure and drive a bus, coach or lorry - download the correct form to let them know
Millions at risk from 'silent killer' as NHS campaign warns there are often 'no clues' when it comes to high blood pressure.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (30 January 2024) approved the medicine momelotinib (Omjjara) to treat the symptoms experienced by adult myelofibrosis patients who have moderate or severe anaemia (a low number of red blood cells...
This study aims to assess the effects of oral iron supplementation in children living in countries where malaria is common
What blood establishments, blood banks and manufacturers of blood products need to do to ensure the safety and quality of blood and blood products.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.